4 recruiting, 3 completed, 1 active not recruiting, 1 not yet recruiting. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 4, Completed 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Hairy Cell Leukemia: new trials by email Literature Review of Hairy Cell Leukemia trials Research Report on Hairy Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | Luminary Therapeutics | 27 | 2026-09-01 | 2026-07-01 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Recruiting | Stanford University | 148 | 2024-03-29 | 2026-08-12 |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant CD22CART cell infusion - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 27 | 2022-05-23 | 2026-10-16 |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. LP-168 - CLL/SLL, Waldenstrom Macroglobulinemia | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 60 | 2021-07-19 | 2026-02-13 |
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience - Hairy Cell Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2019-10-03 | 2026-06-29 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. PLX8394 - Melanoma, Thyroid Cancer | Phase 1 | Terminated | Fore Biotherapeutics | 5 | 2014-02-01 | 2020-10-19 |
| A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Moxetumomab Pasudotox (CAT 8015), CAT 8015 (Moxetumomab Pasudotox) - Hairy Cell Leukemia | Phase 1 | Completed | MedImmune LLC | 49 | 2007-05-10 | 2019-04-02 |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Hairy Cell Leukemia | Phase 1 | Unknown | Cambridge Antibody Technology | 40 | 2007-04-01 | 2007-04-18 |
Leukemia, Hairy Cell (11) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Waldenstrom Macroglobulinemia (3) · Burkitt Lymphoma (2) · Leukemia (2) · Lymphoma (2) · Multiple Myeloma (2) · Recurrence (2) · Anemia (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Leukemia (9) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Blood Protein Disorders (4) · Cardiovascular Diseases (4) · Hemorrhagic Disorders (4)
immunotoxin HA22 (3) · Rituximab (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Acetaminophen (1) · Aspirin (1) · Biological Therapy (1) · Biopsy (1) · CT-P10 (1) · Calcium Dobesilate (1) · Cladribine (1) · Dexamethasone (1) · Diphenhydramine (1) · Famotidine (1) · PLX8394 (1) · Specimen Handling (1)
National Cancer Institute (NCI) (3) · Acerta Pharma BV (1) · Alexey Danilov, MD (1) · Cambridge Antibody Technology (1) · Fore Biotherapeutics (1) · Luminary Therapeutics (1) · MedImmune LLC (1) · Newave Pharmaceutical Inc (1) · Stanford University (1)
United States (11) · Poland (2) · United Kingdom (1)
Robert J Kreitman, M.D. (2) · Craig Okada, M.D. (1) · Matthew Frank, MD, PhD (1) · Seema A Bhat (1) · Sunil Sharma, MD (1)
PMID 41980020, PMID 18596230, PMID 22355053, PMID 29487070, PMID 34196037
UM1CA186712 (1)